The interplay between plasmacytoid and myeloid dendritic cells, helper T cells (Th1, Th17, Th22), and mediators such as tumor necrosis factor (TNF)-α, interleukin (IL)-12, IL-23, and IL-17 provides targets for psoriasis drug development1,2. This evidence concerns the gene TNF and psoriasis.